Zepbound, Lilly's blockbuster injection, has consistently pushed patients past the 20% weight loss mark in trials. The new pill doesn't get anywhere near that number.
Lilly isn't worried.
Foundayo, the freshly approved oral drug, averaged about 12% weight loss in studies - below both Zepbound and Novo Nordisk's competing Wegovy tablet. But CEO Dave Ricks isn't selling potency. He's selling convenience.
Novo's oral Wegovy launched in December and already topped 600,000 prescriptions - an almost unheard-of pace for a brand-new drug.
But it comes with strings attached. Patients have to take it before eating anything in the morning, chase it with just a few ounces of water, and sit tight for 30 minutes before touching food or a drink.
Foundayo skips all of that. Take it whenever, with or without a meal.
For a pill people will swallow every day - potentially for years - that's a real selling point.
Foundayo is a small molecule - the same basic chemistry behind everyday pills like ibuprofen. Zepbound and Wegovy are peptides, which need specialized plants and cold chain shipping to get to patients.
Since 2020, Lilly has funneled more than $55 billion into building out production lines. Ricks says billions of doses are already stockpiled. The company is chasing approval in over 40 countries and plans to start selling wherever regulators sign off.
Novo's Wegovy pill is only available in the U.S. for now. Lilly wants Foundayo on shelves worldwide.
Cash-paying patients start at $149 per month for the entry-level dose and top out at $349 for the strongest version. If you've got private insurance, Lilly is offering a coupon that brings the monthly bill down to $25.
Medicare patients get access this summer at $50 per month - part of a deal both Lilly and Novo cut with the Trump administration.
That pricing matches Novo's entry point dollar for dollar on the low end. Dr. Nidhi Kansal, an obesity specialist at Northwestern Medicine, said cost is still the single biggest factor in which drug patients wind up taking.
Wall Street projects Foundayo will bring in between $15 billion and $18 billion a year by 2030. Solid - but still less than half of what analysts expect from Lilly's injectable Mounjaro.
The number to watch early on is prescriptions. Novo's pill put up a high bar right out of the gate, and Lilly has to match that momentum. A data readout for retatrutide - Lilly's next-generation shot that could top Zepbound's weight loss results - is also on deck.
Lilly's stock rose more than 4% on the news. The bet is clear: the company that makes the daily habit easiest to stick with wins the next phase of this market.
